Literature DB >> 19164356

Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma.

E Derom1, R Louis, C Tiesler, R Engelstätter, J-M Kaufman, G F Joos.   

Abstract

We compared the systemic and clinical effects of ciclesonide (CIC) and fluticasone propionate (FP) administered, in addition to CIC 160 microg x day(-1) and salmeterol 50 microg twice daily, in 32 patients with persistent asthma using a randomised double-blind, placebo-controlled, double-dummy, five-period crossover design. All patients exhibited a provocative concentration leading to a 20% decrease in forced expiratory volume in 1 s (PC(20)) methacholine <8 mg x mL(-1) and a PC(20) adenosine <60 mg x mL(-1). Primary outcome was 24-h serum cortisol suppression after 7 days. Secondary outcomes were changes in PC(20) methacholine and adenosine after 9 days. FP 500 microg x day(-1) and 1,000 microg x day(-1) significantly suppressed cortisol secretion versus placebo by -46.2 (95% confidence interval (CI) -83.8- -8.5) nmol x L(-1) and by -76.1 (95% CI -112.9- -39.3) nmol x L(-1), respectively. Neither dose of CIC (320 nor 640 microg x day(-1)) had a significant suppressive effect (-28.2 (95% CI -65.5-9.2) nmol x L(-1) and -37.3 (95% CI -74.7-0.0) nmol x L(-1), respectively). Differences between FP 1,000 microg x day(-1) and both CIC treatments were statistically significant (CIC 320 microg x day(-1): -48.0 (95% CI -84.8- -11.1) nmol x L(-1); CIC 640 microg x day(-1): -38.8 (95% CI -75.7- -1.9) nmol x L(-1)). Compared with placebo, the increase in PC(20) adenosine after the four treatments was small, but significant. Greater improvements in PC(20) adenosine were seen with FP 500 microg x day(-1) (1.8 (95% CI 1.0-2.6) doubling concentrations) compared with CIC 320 microg x day(-1) (0.9 (95% CI 0.1-1.7) doubling concentrations). No significant difference was seen between CIC 640 microg x day(-1) and FP 1,000 microg x day(-1). For a similar decrease in hyperresponsiveness, cortisol secretion was suppressed significantly with moderate-to-high doses of fluticasone propionate, but not with ciclesonide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164356     DOI: 10.1183/09031936.00079908

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Quantitative Assessment of Pulmonary Targeting of Inhaled Corticosteroids Using Ex Vivo Receptor Binding Studies.

Authors:  Jie Shao; James Talton; Yaning Wang; Lawrence Winner; Guenther Hochhaus
Journal:  AAPS J       Date:  2020-01-30       Impact factor: 4.009

2.  Profile of ciclesonide for the maintenance treatment of asthma.

Authors:  Effie Singas; Jill P Karpel
Journal:  Ther Clin Risk Manag       Date:  2011-08-19       Impact factor: 2.423

3.  Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy.

Authors:  Alexandra Ahmet; Harold Kim; Sheldon Spier
Journal:  Allergy Asthma Clin Immunol       Date:  2011-08-25       Impact factor: 3.406

4.  Comparison of the effect of high-dose inhaled budesonide and fluticasone on adrenal function in patients with severe chronic obstructive pulmonary disease.

Authors:  Ahmed Fahim; Shoaib Faruqi; Caroline E Wright; Jack A Kastelik; Alyn H Morice
Journal:  Ann Thorac Med       Date:  2012-07       Impact factor: 2.219

5.  Budesonide and fluticasone and adrenal suppression.

Authors:  Mona A Fouda; Feisal A Al-Kassimi
Journal:  Ann Thorac Med       Date:  2012-10       Impact factor: 2.219

6.  Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.

Authors:  William W Busse; Paul M O'Byrne; Eugene R Bleecker; Jan Lötvall; Ashley Woodcock; Leslie Andersen; Wesley Hicks; Jodie Crawford; Loretta Jacques; Ludovic Apoux; Eric D Bateman
Journal:  Thorax       Date:  2013-02-25       Impact factor: 9.139

7.  Switching from systemic steroids to ciclesonide restores the hypothalamic pituitary-adrenal axis.

Authors:  Jerzy Marczak; Maciej Ciebiada; Paweł Górski
Journal:  Postepy Dermatol Alergol       Date:  2014-04-22       Impact factor: 1.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.